Harbour BioMed Overview

  • Founded
  • 2016
Founded
  • Status
  • Public
  • Employees
  • 250
Employees
  • Stock Symbol
  • 02142
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $1.20
  • (As of Friday Closing)

Harbour BioMed General Information

Description

HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. Its products under development are Batoclimab, for the treatment of a wide spectrum of autoimmune diseases; Tanfanercept, for the treatment of moderate-to-severe dry eye disease (DED); HBM4003; HBM9022, to prevent and treat COVID-19, the pandemic respiratory disease caused by the SARS-CoV-2 virus; HBM7008; and others. Its geographical segments are Mainland China, United States, Europe, and others.

Contact Information

Formerly Known As
HBM Holdings
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
HKG
Primary Office
  • 1 Broadway, 14th Floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Harbour BioMed Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Harbour BioMed Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.20 $1.18 $1.02 - $1.60 $889M 741M 1.72M -$1.69

Harbour BioMed Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 1,284,616 1,284,616
Revenue 14,107 14,107 5,419 1,483
EBITDA (291,736) (291,736) (63,552) (33,385)
Net Income (296,397) (296,397) (67,460) (34,583)
Total Assets 388,738 388,738 69,499 83,499
Total Debt 1,725 1,725 1,908 3,143
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Harbour BioMed Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Harbour BioMed‘s full profile, request access.

Request a free trial

Harbour BioMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
HBM Holdings Ltd is a clinical-stage biopharmaceutical company engaged in the discovery and development of differentiate
Drug Discovery
Cambridge, MA
250 As of 2021
00000
0.000 0000-00-00
00000000 00000

00000000

o consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000000000000
San Diego, CA
000 As of 0000
00000
000000000 - 00000

000 (000

is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dol
0000 000000000
San Francisco, CA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Harbour BioMed Competitors (56)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sorrento Therapeutics Formerly VC-backed San Diego, CA 000 00000 000000000 - 00000
000 (0000000000000 Formerly VC-backed San Francisco, CA 000 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed Boston, MA 0000 00.000 0000 00.000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
You’re viewing 5 of 56 competitors. Get the full list »

Harbour BioMed Executive Team (10)

Name Title Board Seat Contact Info
Jingsong Wang MD Founder, Chief Executive Officer & Chairman
Atul Deshpande Ph.D Chief Strategy Officer & Head of US Operations
Xiaoxiang Chen MD Chief Development Officer
Mai-Jing Liao Ph.D Chief Business Officer
Louis Liu Senior Vice President & Head of Technology Platform
You’re viewing 5 of 10 executive team members. Get the full list »

Harbour BioMed Board Members (1)

Name Representing Role Since
Jingsong Wang MD Harbour BioMed Founder, Chief Executive Officer & Chairman 000 0000
To view Harbour BioMed’s complete board members history, request access »

Harbour BioMed Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Harbour BioMed Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Harbour BioMed‘s full profile, request access.

Request a free trial

Harbour BioMed Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 19-Dec-2016 000000000000000000 Biotechnology 00000000 0000 00
To view Harbour BioMed’s complete acquisitions history, request access »

Harbour BioMed Subsidiaries (1)

Company Name Industry Location Founded
0000000 0000000000 Biotechnology 0000
To view Harbour BioMed’s complete subsidiaries history, request access »